EZH2 and KDM6B Expressions Are Associated with Specific Epigenetic Signatures during EMT in Non Small Cell Lung Carcinomas
Abstract
:Simple Summary
Abstract
1. Introduction
2. Results
2.1. Both EZH2 and KDM6B Are Overexpressed during EMT in Patients with NSCLCs
2.2. Effects of Overexpression of EZH2 and KDM6B on EMT Induction
2.3. Inhibition of EZH2 and KDM6B Activities Regulated EMT Signaling
2.4. The Genes Targeted by EZH2 and KDM6B during EMT Were Different
2.5. INHBB, WNT5B and ADAMTS6 Established as New Epigenetic Biomarkers of EMT
2.6. Effect of EZH2 and KDM6B Inhibition on INHBB, WNT5B or ADAMTS6 Expression
3. Discussion
4. Materials and Methods
4.1. Cell Culture, Transfections, and Inhibitors Used in Cell Culture
4.2. Invasion and Migration Assays
4.3. Quantitative RT-PCR
4.4. ChIP/ChIP-seq
4.5. Western-Blotting
4.6. Confocal Microscopy
4.7. Immunohistochemistry
4.8. Statistics
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
Abbreviations
ADAM19 | ADAM Metallopeptidase Domain 19 |
ADAMTS6 | ADAM Metallopeptidase with Thrombospondin Type 1 Motif 6 |
BC | Breast Cancer |
ChIP-seq | Chromatin ImmunoPrecipitation-sequencing |
EMT | Epithelial Mesenchymal Transition |
EMC | ExtraCellular Matrix |
EMT-TF | EMT-Transcriptional Factor |
EZH2 | Enhancer of Zeste Homolog 2 |
FFPE | Formalin-Fixed Paraffin-Embedded |
HDM | Histone DeMethylase |
HMT | Histone MethylTransferase |
IF | ImmunoFluorescence |
INHBB | Inhibin Subunit Beta B |
KDM6B | Lysine DeMethylase 6B |
MMP9 | Matrix Metallopeptidase 9 |
NSCLC | Non-Small Cell Lung Carcinoma |
WB | Western-Blotting |
References
- Terry, S.; Savagner, P.; Ortiz-Cuaran, S.; Mahjoubi, L.; Saintigny, P.; Thiery, J.P.; Chouaib, S. New insights into the role of EMT in tumor immune escape. Mol. Oncol. 2017, 11, 824–846. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kalluri, R.; Weinberg, R.A. The basics of epithelial-mesenchymal transition. J. Clin. Investig. 2009, 119, 1420–1428. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Noguchi, K.; Dalton, A.C.; Howley, B.V.; McCall, B.J.; Yoshida, A.; Diehl, J.A.; Howe, P.H. Interleukin-like EMT inducer regulates partial phenotype switching in MITF-low melanoma cell lines. PLoS ONE 2017, 12, e0177830. [Google Scholar] [CrossRef] [PubMed]
- Lehmann, S.; Te Boekhorst, V.; Odenthal, J.; Bianchi, R.; van Helvert, S.; Ikenberg, K.; Ilina, O.; Stoma, S.; Xandry, J.; Jiang, L.; et al. Hypoxia Induces a HIF-1-Dependent Transition from Collective-to-Amoeboid Dissemination in Epithelial Cancer Cells. Curr. Biol. 2017, 27, 392–400. [Google Scholar] [CrossRef] [Green Version]
- Zhu, L.; Li, X.; Chen, Y.; Fang, J.; Ge, Z. High-mobility group box 1: A novel inducer of the epithelial-mesenchymal transition in colorectal carcinoma. Cancer Lett. 2015, 357, 527–534. [Google Scholar] [CrossRef]
- Bacigalupo, M.L.; Manzi, M.; Espelt, M.V.; Gentilini, L.D.; Compagno, D.; Laderach, D.J.; Wolfenstein-Todel, C.; Rabinovich, G.A.; Troncoso, M.F. Galectin-1 triggers epithelial-mesenchymal transition in human hepatocellular carcinoma cells. J. Cell Physiol. 2015, 230, 1298–1309. [Google Scholar] [CrossRef]
- Joseph, J.V.; Conroy, S.; Tomar, T.; Eggens-Meijer, E.; Bhat, K.; Copray, S.; Walenkamp, A.M.; Boddeke, E.; Balasubramanyian, V.; Wagemakers, M.; et al. TGF-beta is an inducer of ZEB1-dependent mesenchymal transdifferentiation in glioblastoma that is associated with tumor invasion. Cell Death Dis. 2014, 5, e1443. [Google Scholar] [CrossRef] [Green Version]
- Miao, J.W.; Liu, L.J.; Huang, J. Interleukin-6-induced epithelial-mesenchymal transition through signal transducer and activator of transcription 3 in human cervical carcinoma. Int. J. Oncol. 2014, 45, 165–176. [Google Scholar] [CrossRef]
- Kim, J.; Kong, J.; Chang, H.; Kim, H.; Kim, A. EGF induces epithelial-mesenchymal transition through phospho-Smad2/3-Snail signaling pathway in breast cancer cells. Oncotarget 2016, 7, 85021–85032. [Google Scholar] [CrossRef] [Green Version]
- Yang, L.; Lin, C.; Liu, Z.R. P68 RNA helicase mediates PDGF-induced epithelial mesenchymal transition by displacing Axin from beta-catenin. Cell 2006, 127, 139–155. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Stoker, M.; Perryman, M. An epithelial scatter factor released by embryo fibroblasts. J. Cell Sci. 1985, 77, 209–223. [Google Scholar] [PubMed]
- Kogure, T.; Kondo, Y.; Kakazu, E.; Ninomiya, M.; Kimura, O.; Shimosegawa, T. Involvement of miRNA-29a in epigenetic regulation of transforming growth factor-beta-induced epithelial-mesenchymal transition in hepatocellular carcinoma. Hepatol. Res. 2014, 44, 907–919. [Google Scholar] [CrossRef] [PubMed]
- Jiang, J.; Yi, B.O.; Ding, S.; Sun, J.; Cao, W.; Liu, M. Demethylation drug 5-Aza-2’-deoxycytidine-induced upregulation of miR-200c inhibits the migration, invasion and epithelial-mesenchymal transition of clear cell renal cell carcinoma in vitro. Oncol. Lett. 2016, 11, 3167–3172. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Asgarova, A.; Asgarov, K.; Godet, Y.; Peixoto, P.; Nadaradjane, A.; Boyer-Guittaut, M.; Galaine, J.; Guenat, D.; Mougey, V.; Perrard, J.; et al. PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma. Oncoimmunology 2018, 7, e1423170. [Google Scholar] [CrossRef] [Green Version]
- Zheng, M.; Jiang, Y.P.; Chen, W.; Li, K.D.; Liu, X.; Gao, S.Y.; Feng, H.; Wang, S.S.; Jiang, J.; Ma, X.R.; et al. Snail and Slug collaborate on EMT and tumor metastasis through miR-101-mediated EZH2 axis in oral tongue squamous cell carcinoma. Oncotarget 2015, 6, 6797–6810. [Google Scholar] [CrossRef] [Green Version]
- Luo, H.; Jiang, Y.; Ma, S.; Chang, H.; Yi, C.; Cao, H.; Gao, Y.; Guo, H.; Hou, J.; Yan, J.; et al. EZH2 promotes invasion and metastasis of laryngeal squamous cells carcinoma via epithelial-mesenchymal transition through H3K27me3. Biochem. Biophys. Res. Commun. 2016, 479, 253–259. [Google Scholar] [CrossRef]
- Li, Z.; Hou, P.; Fan, D.; Dong, M.; Ma, M.; Li, H.; Yao, R.; Li, Y.; Wang, G.; Geng, P.; et al. The degradation of EZH2 mediated by lncRNA ANCR attenuated the invasion and metastasis of breast cancer. Cell Death Differ. 2017, 24, 59–71. [Google Scholar] [CrossRef] [Green Version]
- Li, Q.; Hou, L.; Ding, G.; Li, Y.; Wang, J.; Qian, B.; Sun, J.; Wang, Q. KDM6B induces epithelial-mesenchymal transition and enhances clear cell renal cell carcinoma metastasis through the activation of SLUG. Int. J. Clin. Exp. Pathol. 2015, 8, 6334–6344. [Google Scholar]
- Tang, B.; Qi, G.; Tang, F.; Yuan, S.; Wang, Z.; Liang, X.; Li, B.; Yu, S.; Liu, J.; Huang, Q.; et al. Aberrant JMJD3 Expression Upregulates Slug to Promote Migration, Invasion, and Stem Cell-Like Behaviors in Hepatocellular Carcinoma. Cancer Res. 2016, 76, 6520–6532. [Google Scholar] [CrossRef] [Green Version]
- Lachat, C.; Boyer-Guittaut, M.; Peixoto, P.; Hervouet, E. Epigenetic Regulation of EMT (Epithelial to Mesenchymal Transition) and Tumor Aggressiveness: A View on Paradoxical Roles of KDM6B and EZH2. Epigenomes 2019, 3, 1. [Google Scholar] [CrossRef] [Green Version]
- Gyorffy, B.; Surowiak, P.; Budczies, J.; Lanczky, A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS ONE 2013, 8, e82241. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rath, B.H.; Waung, I.; Camphausen, K.; Tofilon, P.J. Inhibition of the Histone H3K27 Demethylase UTX Enhances Tumor Cell Radiosensitivity. Mol. Cancer Ther 2018, 17, 1070–1078. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Peixoto, P.; Etcheverry, A.; Aubry, M.; Missey, A.; Lachat, C.; Perrard, J.; Hendrick, E.; Delage-Mourroux, R.; Mosser, J.; Borg, C.; et al. EMT is associated with an epigenetic signature of ECM remodeling genes. Cell Death Dis. 2019, 10, 205. [Google Scholar] [CrossRef] [Green Version]
- Wang, Y.; Chen, S.Y.; Colborne, S.; Lambert, G.; Shin, C.Y.; Santos, N.D.; Orlando, K.A.; Lang, J.D.; Hendricks, W.P.D.; Bally, M.B.; et al. Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type. Mol. Cancer Ther. 2018, 17, 2767–2779. [Google Scholar] [CrossRef] [Green Version]
- Das, P.; Taube, J.H. Regulating Methylation at H3K27: A Trick or Treat for Cancer Cell Plasticity. Cancers 2020, 12, 2792. [Google Scholar] [CrossRef]
- Chang, J.W.; Gwak, S.Y.; Shim, G.A.; Liu, L.; Lim, Y.C.; Kim, J.M.; Jung, M.G.; Koo, B.S. EZH2 is associated with poor prognosis in head-and-neck squamous cell carcinoma via regulating the epithelial-to-mesenchymal transition and chemosensitivity. Oral Oncol. 2016, 52, 66–74. [Google Scholar] [CrossRef]
- Ramadoss, S.; Chen, X.; Wang, C.Y. Histone demethylase KDM6B promotes epithelial-mesenchymal transition. J. Biol. Chem. 2012, 287, 44508–44517. [Google Scholar] [CrossRef] [Green Version]
- Herranz, N.; Pasini, D.; Díaz, V.M.; Francí, C.; Gutierrez, A.; Dave, N.; Escrivà, M.; Hernandez-Muñoz, I.; Di Croce, L.; Helin, K.; et al. Polycomb complex 2 is required for E-cadherin repression by the Snail1 transcription factor. Mol. Cell Biol. 2008, 28, 4772–4781. [Google Scholar] [CrossRef] [Green Version]
- Cho, H.M.; Jeon, H.S.; Lee, S.Y.; Jeong, K.J.; Park, S.Y.; Lee, H.Y.; Lee, J.U.; Kim, J.H.; Kwon, S.J.; Choi, E.; et al. microRNA-101 inhibits lung cancer invasion through the regulation of enhancer of zeste homolog 2. Exp. Ther. Med. 2011, 2, 963–967. [Google Scholar] [CrossRef] [Green Version]
- Fu, X.; Lin, J.; Qin, F.; Yang, Z.; Ding, Y.; Zhang, Y.; Han, L.; Zhu, X.; Zhang, Q. LncAPC drives Wnt/β-catenin activation and liver TIC self-renewal through EZH2 mediated APC transcriptional inhibition. Mol. Carcinog. 2018, 57, 408–418. [Google Scholar] [CrossRef] [PubMed]
- Thompson, T.B.; Cook, R.W.; Chapman, S.C.; Jardetzky, T.S.; Woodruff, T.K. Beta A versus beta B: Is it merely a matter of expression? Mol. Cell Endocrinol. 2004, 225, 9–17. [Google Scholar] [CrossRef] [PubMed]
- Kita, A.; Kasamatsu, A.; Nakashima, D.; Endo-Sakamoto, Y.; Ishida, S.; Shimizu, T.; Kimura, Y.; Miyamoto, I.; Yoshimura, S.; Shiiba, M.; et al. Activin B Regulates Adhesion, Invasiveness, and Migratory Activities in Oral Cancer: A Potential Biomarker for Metastasis. J. Cancer 2017, 8, 2033–2041. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zou, G.; Ren, B.; Liu, Y.; Fu, Y.; Chen, P.; Li, X.; Luo, S.; He, J.; Gao, G.; Zeng, Z.; et al. Inhibin B suppresses anoikis resistance and migration through the transforming growth factor-β signaling pathway in nasopharyngeal carcinoma. Cancer Sci. 2018, 109, 3416–3427. [Google Scholar] [CrossRef]
- Kato, S.; Hayakawa, Y.; Sakurai, H.; Saiki, I.; Yokoyama, S. Mesenchymal-transitioned cancer cells instigate the invasion of epithelial cancer cells through secretion of WNT3 and WNT5B. Cancer Sci. 2014, 105, 281–289. [Google Scholar] [CrossRef]
- Shin, Y.J.; Jeon, Y.J.; Jung, N.; Park, J.W.; Park, H.Y.; Jung, S.C. Substrate-specific gene expression profiles in different kidney cell types are associated with Fabry disease. Mol. Med. Rep. 2015, 12, 5049–5057. [Google Scholar] [CrossRef] [Green Version]
- Liu, L.; Yang, Z.; Ni, W.; Xuan, Y. ADAMTS-6 is a predictor of poor prognosis in patients with esophageal squamous cell carcinoma. Exp. Mol. Pathol. 2018, 104, 134–139. [Google Scholar] [CrossRef]
- Raverot, G.; Wierinckx, A.; Dantony, E.; Auger, C.; Chapas, G.; Villeneuve, L.; Brue, T.; Figarella-Branger, D.; Roy, P.; Jouanneau, E.; et al. Prognostic factors in prolactin pituitary tumors: Clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. J. Clin. Endocrinol. Metab. 2010, 95, 1708–1716. [Google Scholar] [CrossRef] [Green Version]
- Jiang, S.; Zhang, M.; Zhang, Y.; Zhou, W.; Zhu, T.; Ruan, Q.; Chen, H.; Fang, J.; Zhou, F.; Sun, J.; et al. WNT5B governs the phenotype of basal-like breast cancer by activating WNT signaling. Cell Commun. Signal. 2019, 17, 109. [Google Scholar] [CrossRef] [Green Version]
- Warda, W.; Larosa, F.; Neto Da Rocha, M.; Trad, R.; Deconinck, E.; Fajloun, Z.; Faure, C.; Caillot, D.; Moldovan, M.; Valmary-Degano, S.; et al. CML Hematopoietic Stem Cells Expressing IL1RAP Can Be Targeted by Chimeric Antigen Receptor-Engineered T Cells. Cancer Res. 2019, 79, 663–675. [Google Scholar] [CrossRef] [Green Version]
- Chen, C.; Khaleel, S.S.; Huang, H.; Wu, C.H. Software for pre-processing Illumina next-generation sequencing short read sequences. Source Code Biol. Med. 2014, 9, 8. [Google Scholar] [CrossRef] [PubMed]
- Herfs, M.; Longuespee, R.; Quick, C.M.; Roncarati, P.; Suarez-Carmona, M.; Hubert, P.; Lebeau, A.; Bruyere, D.; Mazzucchelli, G.; Smargiasso, N.; et al. Proteomic signatures reveal a dualistic and clinically relevant classification of anal canal carcinoma. J. Pathol. 2017, 241, 522–533. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hubert, P.; Herman, L.; Roncarati, P.; Maillard, C.; Renoux, V.; Demoulin, S.; Erpicum, C.; Foidart, J.M.; Boniver, J.; Noel, A.; et al. Altered alpha-defensin 5 expression in cervical squamocolumnar junction: Implication in the formation of a viral/tumour-permissive microenvironment. J. Pathol. 2014, 234, 464–477. [Google Scholar] [CrossRef] [PubMed]
Overlap H3K27me3/EZH2 (ALIAS) | Full Name | Pathway | Downregulated FC |
---|---|---|---|
INHBB | Inhibin Beta B Subunit | Inflammation | −31.8 |
ANK3 | Ankyrin 3 | cytoskeleton | −25 |
CABLES1 | Cdk5 And Abl Enzyme Substrate 1 | cell cycle | −24 |
GREM2 | Gremlin 2, DAN Family BMP Antagonist | differentiation | −12 |
VAV3 | Vav Guanine Nucleotide Exchange Factor 3 | cytoskeleton/signaling | −11.7 |
TC2N | Tandem C2 Domains, Nuclear | −11.5 | |
HR | HR, Lysine Demethylase And Nuclear Receptor Corepressor | EPIGENETICS | −10.7 |
CPLX2 | Complexin 2 | vesicle Trafficking | −10.5 |
COBL | Cordon-Bleu WH2 Repeat Protein | cytoskeleton | −9.5 |
SLC5A11 | Solute Carrier Family 5 Member 11 | metabolism | −9.3 |
C9orf3 | Chromosome 9 Open Reading Frame 3 | M1 zinc aminopeptidase family | −8.4 |
CEACAM7 | Carcinoembryonic Antigen Related Cell Adhesion Molecule 7 | adhesion | −8.4 |
ABLIM1 | Actin-Binding LIM Protein Family Member 1 | cytoskeleton | −8 |
DBP | D-Box Binding PAR BZIP Transcription Factor | TF | −7.8 |
WNT6 | −6.7 | ||
ANK1 | Ankyrin 1 | cytoskeleton | −6.5 |
EFCAB3 | EF-Hand Calcium Binding Domain 3 | calcium | −6.5 |
CXXC5 | CXXC Finger Protein 5 | TF | -6.1 |
FGFR3 | Fibroblast Growth Factor Receptor 3 | signaling | −6 |
MYO5B | Myosin VB | vesicle Trafficking | −6 |
CACNA1G | Calcium Voltage-Gated Channel Subunit Alpha1 G | calcium channel | −5.6 |
PMP22 | Peripheral Myelin Protein 22 | neurones | −5.4 |
PREX1 | Phosphatidylinositol-3,4,5-Trisphosphate Dependent Rac Exchange Factor 1 | signaling | −5.4 |
ANKRD33B | Ankyrin Repeat Domain 33B | cytoskeleton | −4.8 |
PAPLN | Papilin, Proteoglycan Like Sulfated Glycoprotein | peptidase | −4.6 |
C20orf196 | Chromosome 20 Open Reading Frame 196 | −4.5 | |
NR5A2 | Nuclear Receptor Subfamily 5 Group A Member 2 | TF | −4.4 |
NRG2 | Neuregulin 2 | differentiation | −4.4 |
FOXA2 | Forkhead Box A2 | TF | −4.2 |
SYT12 | Synaptotagmin 12 | calcium/neurones/vesicle Trafficking | −4.2 |
LRP2 | LDL Receptor Related Protein 2 | Epithelial/signaling | −4.1 |
NTRK3 | Neurotrophic Receptor Tyrosine Kinase 3 | differentiation/signaling | −4.1 |
CXCL16 | C-X-C Motif Chemokine Ligand 16 | Chemokine | −3.9 |
EGLN3 | Egl-9 Family Hypoxia Inducible Factor 3 | hydroxylase | −3.9 |
KIAA1217 | −3.9 | ||
CEBPA | CCAAT/Enhancer Binding Protein Alpha | TF | −3.8 |
HOXC13 | Homeobox C13 | TF | −3.8 |
NR2F2 | Nuclear Receptor Subfamily 2 Group F Member 2 | TF | −3.8 |
RASSF5 | Ras Association Domain Family Member 5 | signaling | −3.8 |
HRK | Harakiri, BCL2 Interacting Protein | apoptosis | −3.7 |
Overlap KDM6B (ALIAS) | Full Name | Pathway | Upregulated FC |
---|---|---|---|
LAMC2 | Laminin Subunit Gamma 2 | migration | 136.0 |
MMP2 | Matrix Metallopeptidase 2 | invasion | 84.0 |
IFI44 | Interferon Induced Protein 44 | 85.0 | |
PDPN | Podoplanin | adhesion/migration | 70.2 |
EPHB1 | EPH Receptor B1 | signalling/diffenciation | 61.1 |
ADAMTS6 | ADAM Metallopeptidase with Thrombospondin Type 1 Motif 6 | invasion | 60.8 |
PLXNA2 | Plexin A2 | neurones/cytoskeleton | 51.3 |
CORO2B | Coronin 2B | cytoskeleton | 50.5 |
WNT5B | Wnt Family Member 5B | signaling | 49.2 |
FGF1 | Fibroblast Growth Factor 1 | invasion | 46.8 |
IL11 | Interleukin 11 | inflammation | 40.9 |
SERPINE1 | Serpin Family E Member 1 | TGF signaling | 36.2 |
SORBS2 | Sorbin And SH3 Domain Containing 2 | signaling | 32.8 |
ST3GAL1 | ST3 Beta-Galactoside Alpha-2,3-Sialyltransferase 1 | golgi/metabolism | 31.0 |
ADRB2 | Adrenoceptor Beta 2 | signalling | 29.2 |
FLRT2 | Fibronectin Leucine Rich Transmembrane Protein 2 | migration/neurones | 29.1 |
CCBE1 | Collagen And Calcium Binding EGF Domains 1 | invasion | 27.7 |
ITGA1 | Integrin Subunit Alpha 1 | adhesion/inflammation | 25.3 |
GABBR2 | Gamma-Aminobutyric Acid Type B Receptor Subunit 2 | signalling | 25.1 |
CNTNAP2 | Contactin Associated Protein Like 2 | neurones/adhesion | 24.9 |
TSPAN2 | Tetraspanin 2 | sgnaling/migration | 23.5 |
MAMDC2 | MAM Domain Containing 2 | 22.5 | |
ABLIM3 | Actin Binding LIM Protein Family Member 3 | cytoskeleton | 21.1 |
PDE11A | Phosphodiesterase 11A | signaling | 22.0 |
SPOCK1 | SPARC/Osteonectin, Cwcv And Kazal Like Domains Proteoglycan 1 | 18.5 | |
FHOD3 | Formin Homology 2 Domain Containing 3 | cytoskeleton | 17.9 |
LPAR5 | Lysophosphatidic Acid Receptor 5 | signalling | 17.8 |
KIF26B | Kinesin Family Member 26B | vesicle trafficking/cancer | 17.6 |
STC1 | Stanniocalcin 1 | metabolism | 15.4 |
FILIP1L | Filamin A Interacting Protein 1 Like | cell division/invasion regulation | 15.4 |
GPAM | Glycerol-3-Phosphate Acyltransferase, Mitochondrial | metabolism | 15.3 |
FRMD6 | FERM Domain Containing 6 | 14.9 | |
COL1A1 | Collagen Type I Alpha 1 Chain | invasion | 14.1 |
PID1 | Phosphotyrosine Interaction Domain Containing 1 | 14.0 | |
NTN1 | Netrin 1 | migration | 13.9 |
CDCP1 | CUB Domain Containing Protein 1 | invasion | 13.3 |
SCG5 | Secretogranin V | protein transport | 12.4 |
TNS1 | Tensin 1 | adhesion | 12.0 |
CUX2 | Cut Like Homeobox 2 | TF | 11.9 |
COL13A1 | Collagen Type XIII Alpha 1 Chain | invasion | 11.9 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lachat, C.; Bruyère, D.; Etcheverry, A.; Aubry, M.; Mosser, J.; Warda, W.; Herfs, M.; Hendrick, E.; Ferrand, C.; Borg, C.; et al. EZH2 and KDM6B Expressions Are Associated with Specific Epigenetic Signatures during EMT in Non Small Cell Lung Carcinomas. Cancers 2020, 12, 3649. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers12123649
Lachat C, Bruyère D, Etcheverry A, Aubry M, Mosser J, Warda W, Herfs M, Hendrick E, Ferrand C, Borg C, et al. EZH2 and KDM6B Expressions Are Associated with Specific Epigenetic Signatures during EMT in Non Small Cell Lung Carcinomas. Cancers. 2020; 12(12):3649. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers12123649
Chicago/Turabian StyleLachat, Camille, Diane Bruyère, Amandine Etcheverry, Marc Aubry, Jean Mosser, Walid Warda, Michaël Herfs, Elodie Hendrick, Christophe Ferrand, Christophe Borg, and et al. 2020. "EZH2 and KDM6B Expressions Are Associated with Specific Epigenetic Signatures during EMT in Non Small Cell Lung Carcinomas" Cancers 12, no. 12: 3649. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers12123649